Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity
- PMID: 2510141
- DOI: 10.1023/a:1015934321764
Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity
Abstract
The following valpromide (VPD) derivatives were synthesized and their structure-pharmacokinetic relationships explored: ethylbutylacetamide (EBD), methylpentylacetamide (MPD), propylisopropylacetamide (PID), and propylallylacetamide (PAD). In addition, the anticonvulsant activity of these compounds was evaluated and compared to that of VPD, valnoctamide (VCD), and valproic acid (VPA). MPD, the least-branched compound had the largest clearance and shortest half-life of all the amides investigated and was the least active. All other amides had similar pharmacokinetic parameters. Unlike the other amides, PID and VCD did not metabolize to their respective homologous acids and were the most active compounds. Our study showed that these amides need an unsubstituted beta position in their aliphatic side chain in order to biotransform to their homologous acids. An amide which is not metabolized is more potent as an anticonvulsant than its biotransformed isomer. All amides were more active than their respective homologous acids. In this particular series of aliphatic amides, which were derived from short-branched fatty acids, the anticonvulsant activity was affected by the pharmacokinetics in general and by the biotransformation of the amide to its homologous acid in particular. This amide-acid biotransformation appeared to be dependent upon the chemical structure, especially upon the substitution at position beta of the molecule.
Similar articles
-
Can we develop improved derivatives of valproic acid?Pharm World Sci. 1994 Feb 18;16(1):2-6. doi: 10.1007/BF01870931. Pharm World Sci. 1994. PMID: 8156045 Review.
-
Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity.J Pharm Sci. 1990 Aug;79(8):719-24. doi: 10.1002/jps.2600790814. J Pharm Sci. 1990. PMID: 2231336
-
Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide.Pharm Res. 1996 Feb;13(2):284-9. doi: 10.1023/a:1016055517724. Pharm Res. 1996. PMID: 8932450
-
Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats.Drug Metab Dispos. 1996 May;24(5):560-4. Drug Metab Dispos. 1996. PMID: 8723737
-
The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus.Epilepsy Behav. 2015 Aug;49:298-302. doi: 10.1016/j.yebeh.2015.04.012. Epub 2015 May 13. Epilepsy Behav. 2015. PMID: 25979572 Review.
Cited by
-
Can we develop improved derivatives of valproic acid?Pharm World Sci. 1994 Feb 18;16(1):2-6. doi: 10.1007/BF01870931. Pharm World Sci. 1994. PMID: 8156045 Review.
-
2D and 3D QSAR analysis of some valproic acid metabolites and analogues as anticonvulsant agents.Pharm Res. 2000 Jun;17(6):727-32. doi: 10.1023/a:1007538517470. Pharm Res. 2000. PMID: 10955848
-
Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile.Molecules. 2021 Dec 24;27(1):104. doi: 10.3390/molecules27010104. Molecules. 2021. PMID: 35011339 Free PMC article. Review.
-
Valproic Acid: second generation.Neurotherapeutics. 2007 Jan;4(1):130-7. doi: 10.1016/j.nurt.2006.11.007. Neurotherapeutics. 2007. PMID: 17199028 Free PMC article. Review.
-
Clinical pharmacology of valpromide.Clin Pharmacokinet. 1991 Feb;20(2):114-22. doi: 10.2165/00003088-199120020-00003. Clin Pharmacokinet. 1991. PMID: 2029804 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources